FI963571A0 - Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi - Google Patents
Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksiInfo
- Publication number
- FI963571A0 FI963571A0 FI963571A FI963571A FI963571A0 FI 963571 A0 FI963571 A0 FI 963571A0 FI 963571 A FI963571 A FI 963571A FI 963571 A FI963571 A FI 963571A FI 963571 A0 FI963571 A0 FI 963571A0
- Authority
- FI
- Finland
- Prior art keywords
- conditions associated
- treating conditions
- 5ht2b receptor
- 5ht2b
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21262294A | 1994-03-11 | 1994-03-11 | |
US08/380,565 US5663178A (en) | 1995-02-06 | 1995-02-06 | Tetrahydro-beta carbolines |
US08/380,566 US5688807A (en) | 1994-03-11 | 1995-02-06 | Method for treating 5HT2B receptor related conditions |
PCT/US1995/003099 WO1995024200A1 (en) | 1994-03-11 | 1995-03-10 | Method for treating 5ht2b receptor related conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
FI963571A0 true FI963571A0 (fi) | 1996-09-10 |
FI963571A FI963571A (fi) | 1996-11-08 |
Family
ID=27395770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI963571A FI963571A (fi) | 1994-03-11 | 1996-09-10 | Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0749313A4 (fi) |
JP (1) | JPH09510216A (fi) |
CN (1) | CN1148340A (fi) |
AU (1) | AU679635B2 (fi) |
CA (1) | CA2185236A1 (fi) |
CZ (1) | CZ264996A3 (fi) |
FI (1) | FI963571A (fi) |
HU (1) | HUT75522A (fi) |
IL (1) | IL112958A0 (fi) |
NO (1) | NO963785L (fi) |
WO (1) | WO1995024200A1 (fi) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
JPH11503757A (ja) * | 1995-04-18 | 1999-03-30 | イーライ・リリー・アンド・カンパニー | 5−ht▲下7▼レセプターにおいて生理学的および病理学的機能を生じるエルゴリン化合物の使用方法 |
GB9523999D0 (en) | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
AU724646B2 (en) * | 1996-03-15 | 2000-09-28 | Eli Lilly And Company | Method of treating common cold or allergic rhinitis |
US5880134A (en) * | 1996-03-20 | 1999-03-09 | Eli Lilly And Company | Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor |
NZ332037A (en) * | 1996-03-25 | 2001-01-26 | Lilly Co Eli | Olanzapine for treating migraine pain |
US5886003A (en) * | 1996-03-25 | 1999-03-23 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of venomous bites and stings |
EA199800867A1 (ru) * | 1996-03-25 | 1999-02-25 | Эли Лилли Энд Компани | Соединения тетрагидробетакарболина |
WO2000069437A1 (en) | 1999-05-18 | 2000-11-23 | Synaptic Pharmaceutical Corporation | Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder |
DE60022504T2 (de) | 1999-05-24 | 2006-06-29 | Mitsubishi Pharma Corp. | Phenoxypropylamin-derivate |
US6444477B1 (en) * | 2000-11-28 | 2002-09-03 | Pharmagene Laboratories Limited | Assay method for detecting 5-HT2B antagonists |
GB0203412D0 (en) | 2002-02-13 | 2002-04-03 | Pharmagene Lab Ltd | 5-HT 2B receptor antagonists |
ES2313002T3 (es) * | 2003-05-09 | 2009-03-01 | Laboratorios Del Dr. Esteve, S.A. | Uso de derivados de sulfonamida para la fabricacion de un medicamento para la profilaxis y/o tratamiento de la ingestion de alimentos. |
JP4998258B2 (ja) * | 2005-02-08 | 2012-08-15 | アステラス製薬株式会社 | 過敏性腸症候群の治療薬 |
JP5092746B2 (ja) | 2005-08-08 | 2012-12-05 | アステラス製薬株式会社 | アシルグアニジン誘導体またはその塩 |
CA2642619A1 (en) * | 2006-02-20 | 2007-08-30 | Astellas Pharma Inc. | Pyrrole derivative or salt thereof |
CN102083830B (zh) | 2008-03-24 | 2014-11-12 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚和应用方法 |
MX2011005221A (es) | 2008-11-21 | 2011-08-03 | Raqualia Pharma Inc | Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b. |
TW201038569A (en) * | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
CA2775129A1 (en) * | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[3,4-b]indoles and methods of use |
CN102724875B (zh) * | 2009-09-23 | 2015-05-27 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚化合物及其使用方法 |
AU2017242027B2 (en) | 2016-04-01 | 2020-10-08 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
JP2022523774A (ja) * | 2019-02-27 | 2022-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脳障害を治療するためのn-置換インドール及び他の複素環化合物 |
BR112022002138A2 (pt) | 2019-08-06 | 2022-04-19 | Recurium Ip Holdings Llc | Moduladores do receptor de estrogênio para tratamento de mutantes |
WO2023143393A1 (zh) * | 2022-01-29 | 2023-08-03 | 上海科技大学 | 三并环类化合物、其制备方法和用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3492304A (en) * | 1968-06-24 | 1970-01-27 | Warner Lambert Pharmaceutical | 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones |
DE3240514A1 (de) * | 1982-10-29 | 1984-05-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
US4520024A (en) * | 1983-02-11 | 1985-05-28 | Eli Lilly And Company | Method of selectively blocking peripheral vascular serotonergic receptors |
US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
EP0620222A3 (en) * | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
-
1995
- 1995-03-10 HU HU9602482A patent/HUT75522A/hu unknown
- 1995-03-10 IL IL11295895A patent/IL112958A0/xx unknown
- 1995-03-10 CN CN95193029A patent/CN1148340A/zh active Pending
- 1995-03-10 WO PCT/US1995/003099 patent/WO1995024200A1/en not_active Application Discontinuation
- 1995-03-10 EP EP95914014A patent/EP0749313A4/en not_active Withdrawn
- 1995-03-10 CA CA002185236A patent/CA2185236A1/en not_active Abandoned
- 1995-03-10 JP JP7523692A patent/JPH09510216A/ja active Pending
- 1995-03-10 AU AU21186/95A patent/AU679635B2/en not_active Ceased
- 1995-03-10 CZ CZ962649A patent/CZ264996A3/cs unknown
-
1996
- 1996-09-10 FI FI963571A patent/FI963571A/fi unknown
- 1996-09-10 NO NO963785A patent/NO963785L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CN1148340A (zh) | 1997-04-23 |
IL112958A0 (en) | 1995-06-29 |
EP0749313A1 (en) | 1996-12-27 |
HU9602482D0 (en) | 1996-11-28 |
AU679635B2 (en) | 1997-07-03 |
JPH09510216A (ja) | 1997-10-14 |
AU2118695A (en) | 1995-09-25 |
CZ264996A3 (cs) | 1998-01-14 |
CA2185236A1 (en) | 1995-09-14 |
FI963571A (fi) | 1996-11-08 |
HUT75522A (en) | 1997-05-28 |
NO963785L (no) | 1996-11-01 |
WO1995024200A1 (en) | 1995-09-14 |
NO963785D0 (no) | 1996-09-10 |
EP0749313A4 (en) | 2001-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI963571A0 (fi) | Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi | |
FI940487A0 (fi) | Vianmääritysmenetelmä kehitysprosessia varten | |
FI954863A (fi) | Parannettu menetelmä polymeerien muodostamiseksi | |
DE69534965D1 (de) | Abscheidungsverfahren | |
FI971568A0 (fi) | Menetelmä resistenttien kasvainten hoitamiseksi | |
DE69506072D1 (de) | Strickverfahren | |
DE69520558T2 (de) | Halogenierungsverfahren | |
HK1018985A1 (en) | Method for manufacturing cladding material. | |
ZA952022B (en) | Method for treating 5HT2B receptor related conditions | |
GB9422674D0 (en) | Knitting method | |
GB2297562B (en) | Knitting method | |
TR199500953A1 (tr) | Sac büyümesini saglayan yöntem. | |
EP0669428A3 (en) | Method of laying roads. | |
GB2289946B (en) | Method | |
DE69507032D1 (de) | Chlorhydrin-verfahren | |
FI971675A0 (fi) | Menetelmä bradykiniinin liittyvien tilojen inhiboimiseksi | |
FI931051A0 (fi) | Kuvausmenetelmä | |
GB9400227D0 (en) | Validation method | |
DE59502715D1 (de) | Ansteuerungsverfahren für DHF-LCD | |
FI962626A (fi) | Menetelmä hiokkeen valmistusprosessin ohjaamiseksi | |
GB2294955B (en) | Knitting method | |
FI942585A0 (fi) | Menetelmä kaapelin jatkamiseksi | |
FI970906A0 (fi) | Säätelymenetelmä | |
LV10943A (lv) | N-benziloksikarbonilarginina 4-metilkumaril-7-amida iegusanas metode | |
GB9412568D0 (en) | Knitting method |